<DOC>
	<DOCNO>NCT01757366</DOCNO>
	<brief_summary>Safety Efficacy Ginsenoside Rg3 Combination First-line Chemotherapy Advanced Gastric Cancer.The purpose study assess safety Ginsenoside Rg3 advance gastric cancer , whether improves efficacy first-line chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Ginsenoside Rg3 Combination With First-line Chemotherapy Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent form 2 . Performance Status Eastern Cooperative Oncology Group ( ECOG ) 01 ; 3 . Histologically cytologically confirm gastric cancer ; 4 . At least one measurable disease ( accord RECIST , Response Evaluation Criteria Solid Tumors ) 5 . Life expectancy least 3 month ; 1 . Received prior treatment include Ginsenoside Rg3 ; 2 . Active uncontrolled infection ; 3 . Concurrent treatment investigational agent participation another therapeutic clinical trial ; 4 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>